{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-004263","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.223147+00:00","generated_at":"2026-06-20T12:00:56.160738+00:00","sec_items":["1.01","3.03","7.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Allarity Therapeutics extends Series A conversion price adjustment indefinitely; discloses 2023 budget of ~$21.7M","bullets":["Conversion price (lower of closing price or 5-day avg) for Series A Preferred now indefinite per amendment with 3i, LP.","Proposed 2023 budget: $4.9M milestone payments, $10.5M development costs, $6.3M G&A; total ~$21.7M.","Company intends to finance budget through capital raising; no assurance of sufficient capital.","Series A Preferred issued in May 2021; 3i also holds a secured promissory note from November 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-004263","json":"https://secwatch.observer/filing/0001213900-23-004263.json","markdown":"https://secwatch.observer/filing/0001213900-23-004263.md","text":"https://secwatch.observer/filing/0001213900-23-004263.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023004263/0001213900-23-004263-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023004263/ea172038-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T12:00:56.160738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"16a01112788f1d9aa4f77d2010e9c2eab3b59eb7","claim":"Allarity Therapeutics, Inc. amended Letter Agreement with 3i, LP valued at Amendment to extend conversion price modification until terminated by Company and 3i (effective 2023-01-23).","evidence_excerpt":"On January 23, 2023, the Company and 3i amended the Letter Agreement to provide the term Conversion Price will be in effect until terminated by the Company and 3i.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023004263/0001213900-23-004263-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"3i, LP"},{"label":"Value","value":"Amendment to extend conversion price modification until terminated by Company and 3i"},{"label":"Effective","value":"2023-01-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}